RecruitingPhase 1NCT06812052

Short Course Radiation Treatment for Patients With Primary or Locally Recurrent Retroperitoneal Sarcoma Prior to Surgery

Prospective Phase I Trial of Hypofractionated Radiation Therapy in Retroperitoneal Sarcoma


Sponsor

Brigham and Women's Hospital

Enrollment

6 participants

Start Date

May 29, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

To determine the safety of moderately hypofractionated radiation in the treatment of primary and locally recurrent RPS, based on the evaluation of acute radiation-related toxicity profile of each participant (30-day radiation toxicity)


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing short-course radiation therapy given before surgery for retroperitoneal sarcoma — a rare, aggressive soft tissue cancer that forms in the back of the abdominal cavity. The goal is to shrink the tumor before removing it surgically. **You may be eligible if...** - You are 18 or older - You have been diagnosed with a soft tissue sarcoma in the retroperitoneal space (deep abdominal area) - Your tumor is measurable on CT or MRI imaging - Surgery and radiation are both considered feasible based on imaging and specialist review - Your general health status is adequate (ECOG ≤2) **You may NOT be eligible if...** - You have a history of bowel obstruction, serious inflammatory bowel disease, or mesenteric ischemia - Your kidney function is impaired - Your tumor is not suitable for an R0 or R1 surgical resection - You do not meet the required performance status Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

RADIATIONRadiation Therapy

In this study, patients will receive a hypofractionated course of radiation therapy of 2.85 Gy x 15 fractions (42.75 Gy). If there are 2 or more patients with dose-limiting toxicities, the radiation course will be de-escalated to 2.7 Gy x 15 fractions (40.5 Gy).

RADIATIONHypofractionationed Radiation Therapy

This group is receiving hypofractionated radiation therapy (shorter course of RT)


Locations(1)

Brigham and Women's Hospital / Dana Farber Cancer Institute

Boston, Massachusetts, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06812052


Related Trials